Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection

HIV Clinical Trials

Volumn 7, Issue 5, 2006, Pages 229-236

  Ruane, Peter ^a   Lang, Joseph ^b   DeJesus, Edwin ^c   Berger, Daniel S ^d   Dretler, Robin ^e   Rodriguez, Allan ^f   Ward, Douglas J ^g   Lim, Michael L ^h,j   Liao, Qiming ^h   Reddy, Sunila ^h   St Clair, Marty ^h   Vila, Tania ⁱ   Shaefer, Mark S ^h  

^a Private Practice   (United States)

^b ID Consultants   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Northstar Medical Center   (United States)

^e IDS   (United States)

^f UNIVERSITY OF MIAMI   (United States)

^g Dupont Circle Physician's Group   (United States)

^h GLAXOSMITHKLINE   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

Abacavir; Anti HIV agents; Efavirenz; HAART; HIV; Iamivudine; Once daily patient compliance; Zidovudine

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; VIRUS RNA;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FLATULENCE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; PILOT STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; SODIUM BLOOD LEVEL; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 33845707871     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0705-229     Document Type: Article

References (12)

1. Department of Health and Human Services (DHHS) and the Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, May 4, 2006. Available at: www.aidsinfo.nih.gov. Accessed July 3, 2006.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998:338:853-860.
3. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
4. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000:133:21-30.
5. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38:445-448.
6. Ruane PJ, Parenti DM, Margolis DM, et al. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. HIV Clin Trials. 2003;4(4):231-243.
7. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/ lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):257-264.
8. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-1861.
9. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38(4):417-425.
10. DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naïve adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39(3):411-418.
11. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25): 1865-1873.
12. Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve subjects infected with human immunodeficiency virus. Pharmacotherapy. 2004;24(3):307-312.